![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Once-Daily Sofosbuvir Plus Ribavirin Given for 12 or 24 Weeks in Treatment-Naïve Patients
With HCV Infection: the QUANTUM Study
|
|
|
Reported by Jules Levin
EASL 2013 Amsterdam April 27, 2013
Jay P. Lalezari1, David R. Nelson2, Robert H. Hyland3, Ming Lin3, Stephen J. Rossi4, William T. Symonds3, Maribel Rodriguez-Torres5, Eric J. Lawitz6
1Quest Clinical Research, San Francisco, CA, USA; 2University of Florida, Gainesville, FL, USA; 3Gilead Sciences, Inc., Foster City, CA; 4SJR Consulting, San Francisco, CA, USA; 5Fundación de Investigación de Diego, Rio Piedras, Puerto Rico; 6Texas Liver Institute, San Antonio, TX, USA
![EASL1.gif](../images/042813/042813-1/EASL1.gif)
![EASL2.gif](../images/042813/042813-1/EASL2.gif)
![EASL3.gif](../images/042813/042813-1/EASL3.gif)
![EASL4.gif](../images/042813/042813-1/EASL4.gif)
![EASL5.gif](../images/042813/042813-1/EASL5.gif)
![EASL6.gif](../images/042813/042813-1/EASL6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|